69 recruiting, 62 completed, 43 not yet recruiting, 9 unknown. 82 Not applicable, 44 Phase 2, 26 Phase 3, 14 Phase 1, 11 Phase 4.
Follow Major Depressive Disorder (MDD): new trials by email Literature Review of Major Depressive Disorder (MDD) trials Research Report on Major Depressive Disorder (MDD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iMORE+ Study: A Multi-Omics Cohort Study of Major Depressive Disorder Major Depressive Disorder (MDD) | Not yet recruiting | Shanghai Mental Health Center | 150 | 2027-09-01 | 2026-08-03 | |
| Evaluation of the Acceptability, Feasibility and Exploration of the Efficacy of an Integrated Care Pathway CARIBOU CARIBOU Integrated Care Pathway, Treatment as Usual (TAU) - Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | Universidad de los Andes, Chile | 72 | 2027-07-01 | 2026-10-20 |
| Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation. Major Depressive Disorder (MDD) | Not yet recruiting | Sohag University | 90 | 2027-03-14 | 2026-08-20 | |
| Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications repetitive transcranial magnetic stimulation (rTMS) - Schizophrenia, Bipolar Disorder | Not applicable | Not yet recruiting | Central South University | 400 | 2027-01-01 | 2026-03-04 |
| Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression. K-ACT Intervention - Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | University of British Columbia | 50 | 2027-01-01 | 2026-10-30 |
| EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG - Major Depressive Disorder (MDD), Treatment Resistant Depression | Not applicable | Not yet recruiting | Mayo Clinic | 60 | 2026-11-01 | 2026-10-16 |
| Ketogenic Diet and Neuromodulation in Treatment Resistant Depression Accelerated Intermittent Theta Burst Stimulation (iTBS), Ketogenic Diet, Canadian Food Guide-Aligned Diet - Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD) | Not applicable | Recruiting | Sunnybrook Health Sciences Centre | 60 | 2026-10-21 | 2026-10-28 |
| Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS) - Opioid Use Disorder, Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | University of Kentucky | 60 | 2026-10-15 | 2026-09-25 |
| Home-Based Randomized Trial of Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression Spaced Transcranial Direct Current Stimulation (tDCS), Sham Spaced tDCS - Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | University of California, San Diego | 74 | 2026-10-15 | 2026-09-22 |
| Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive Disorder Temporal Interference transcranial Alternating Current Stimulation (TI-tACS), Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) - Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | Central South University | 102 | 2026-10-10 | 2026-10-21 |
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts Ketamine hydrochloride infusion - Major Depressive Disorder (MDD) | Phase 4 | Not yet recruiting | New York State Psychiatric Institute | 12 | 2026-10-01 | 2026-08-03 |
| Oral Thiamine (Vitamin B1) for Depression in Children and Adolescents thiamine hydrochloride 100 mg - Major Depressive Disorder (MDD), Thiamine | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2026-10-01 | 2026-08-28 |
| Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial Transcranial Magnetic Stimulation - Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 160 | 2026-10-01 | 2026-09-18 |
| Effect of TMS Treatment on Defense Mechanisms and Functionality in Patients With Depression Major Depressive Disorder (MDD) | Not yet recruiting | Namik Kemal University | 50 | 2026-10-01 | 2026-10-13 | |
| Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder Pregnenolone, Placebo - Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | Phase 2 | Not yet recruiting | Sherwood Brown, MD, PhD | 100 | 2026-10-01 | 2026-08-24 |
| Prescribing the Right Agent for Depression in Adults PRADA Tool, PETRUSHKA Tool - Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | University of Oxford | 2142 | 2026-10-01 | 2026-10-09 |
| Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Sertraline - Major Depressive Disorder (MDD), Probiotic Intervention | Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2026-10-01 | 2026-06-12 |
| A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder ALKS 7290 Dose, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Alkermes, Inc. | 180 | 2026-10-01 | 2026-10-28 |
| Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy Lurasidone, Placebo, Background Antidepressant Therapy - Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | Phase 3 | Not yet recruiting | Bukwang Pharmaceutical | 364 | 2026-09-28 | 2026-09-16 |
| Individualized fMRI-guided TMS for Depression Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Transcranial Magnetic Stimulation (TMS) - Depression, Major Depressive Disorder (MDD) | Early Phase 1 | Not yet recruiting | University of Pennsylvania | 60 | 2026-09-15 | 2026-09-09 |
Showing 20 of 207. Sign in to see all of them.
Depressive Disorder, Major (207) · Depression (58) · Depressive Disorder, Treatment-Resistant (17) · Anxiety Disorders (10) · Bipolar Disorder (10) · Generalized Anxiety Disorder (7) · Alcoholism (6) · Depressive Disorder (6) · Mental Disorders (6) · Suicidal Ideation (6) · Alzheimer Disease (5) · Schizophrenia (5) · Cognitive Dysfunction (4) · Mood Disorders (4) · Motor Activity (4)
Mood Disorders (203) · Depressive Disorder (201) · Mental Disorders (201) · Behavior (71) · Behavioral Symptoms (64) · Nervous System Diseases (17) · Pathological Conditions, Signs and Symptoms (14) · Bipolar and Related Disorders (9) · Central Nervous System Diseases (8) · Chemically-Induced Disorders (8) · Neurocognitive Disorders (8) · Brain Diseases (7) · Pathologic Processes (7) · Signs and Symptoms (7) · Alcohol-Related Disorders (6)
Escitalopram (11) · Transcranial Magnetic Stimulation (11) · Therapeutics (7) · Aripiprazole (6) · Cognitive Behavioral Therapy (6) · Exercise (5) · Ketamine (5) · Sertraline (5) · Selective Serotonin Reuptake Inhibitors (4) · Duloxetine Hydrochloride (3) · Fluoxetine (3) · Transcranial Direct Current Stimulation (3) · agomelatine (3) · ammoxetine (3) · Amisulpride (2)
GlaxoSmithKline (10) · Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Shanghai Mental Health Center (6) · Central South University (4) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (4) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (3) · Chengdu Kanghong Pharmaceutical Group Co., Ltd. (3) · IRCCS Centro San Giovanni di Dio Fatebenefratelli (3) · The University of Hong Kong (3) · University of British Columbia (3) · University of Pennsylvania (3) · Capital Medical University (2) · Centre for Addiction and Mental Health (2) · Draig Therapeutics Ltd (2) · Eli Lilly and Company (2)
United States (67) · China (32) · Canada (21) · Germany (9) · Czechia (8) · Spain (8) · Turkey (Türkiye) (7) · Bulgaria (6) · Poland (6) · Australia (5) · India (5) · Italy (5) · Pakistan (5) · United Kingdom (5) · France (4)
David Walling, Ph.D. (2) · Huafang LI, MD PhD (2) · Jennifer Phillips, PhD (2) · Raymond W. Lam, MD, FRCPC (2) · TianHong Zhang, Doctor (2) · Albert R Powers, MD, PhD (1) · Alexander J. Kiss, Dr. (1) · Amit Lazarov, PhD (1) · Amy HY Cheung, Dr. (1) · Anthony J. Levitt, Dr. (1) · Ashwin A Patkar, MD (1)
PMID 31784354, PMID 16136173, PMID 16848645, PMID 16974189, PMID 20361916, PMID 22203317, PMID 23982301, PMID 24029535, PMID 24438321, PMID 25271445, PMID 26580307, PMID 26693034, PMID 27035159, PMID 27089159, PMID 27685842, PMID 27784751, PMID 28496402, PMID 28686990, PMID 28942738, PMID 29137655, PMID 29153927, PMID 30063303, PMID 30264149, PMID 30368163, PMID 30503621, PMID 30596524, PMID 30677646, PMID 31721487, PMID 31881956, PMID 34894307, PMID 35483736, PMID 35579606, PMID 35963181, PMID 36692954, PMID 37164957, PMID 37716637, PMID 37839775, PMID 38676734, PMID 39268031, PMID 39440449, PMID 40982284, PMID 41134764, PMID 41149679, PMID 41196855, PMID 41210143, PMID 41425080, PMID 42264114, PMID 42289374, PMID 42476741
2025 (4), 1UG3DA066242-01 (1), 2019 (1), 2023 (1), K23MH144148 (1), R01AA033156 (1), R01MH068376 (1), R01MH095809 (1), R01MH137211 (1), R21MH130870 (1), R21MH137546 (1), R33MH135428 (1), R34MH094535 (1)